Aura Biosciences (AURA) Liabilities and Shareholders Equity (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $137.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 11.41% year-over-year to $137.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $701.5 million (down 7.88% YoY) and the FY2025 annual result came in at $169.4 million, down 7.16% from the prior year.
• Liabilities and Shareholders Equity declined to $137.7 million in Q1 2026, from $169.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $255.1 million in Q4 2023 to a low of $135.0 million in Q2 2022.
• A 5-year average of $187.1 million and a median of $190.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 57.82% — and 2025, when it sank 33.88%.
• Tracing AURA's Liabilities and Shareholders Equity over 5 years: stood at $223.9 million in 2022, then advanced by 13.91% to $255.1 million in 2023, then dropped by 28.45% to $182.5 million in 2024, then dropped by 7.16% to $169.4 million in 2025, then slipped by 18.74% to $137.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $137.7 million (Q1 2026), $169.4 million (Q4 2025), and $190.0 million (Q3 2025), per Business Quant data.